Olema Pharmaceuticals, Inc. 8-K

What Happened

• Olema Pharmaceuticals, Inc. announced and furnished a press release on March 16, 2026 reporting its financial results for the year ended December 31, 2025. The company filed an 8-K (Item 2.02) to disclose these results and included the press release as an exhibit. The report is signed by President and CEO Sean Bohen, M.D., Ph.D.

Key Details

• Filing date: March 16, 2026 (8-K reporting results under Item 2.02).
• Reporting period: year ended December 31, 2025.
• Exhibit included: Press Release dated March 16, 2026 (Exhibit 99.1) and the Cover Page Interactive Data File (Inline XBRL).
• The 8-K was executed by Sean Bohen, M.D., Ph.D., President and Chief Executive Officer.

Why It Matters

• Annual financial results are material information that can affect investor views on the company’s performance, outlook, and valuation.
• The furnished press release contains the detailed figures and commentary investors should review (the 8-K itself references the press release rather than embedding the full financial tables).
• Retail investors should read the March 16, 2026 press release and monitor subsequent filings (e.g., Form 10-K) for full audited results, management discussion, and implications for cash runway, R&D funding, and corporate plans.